Cargando…

Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003

The development of an efficacious DENV vaccine has been a long-standing public health priority. However, this effort has been complicated significantly due to the hazard presented by incomplete humoral immunity in mediating immune enhancement of infection and disease severity. Therefore, there is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waickman, Adam T., Friberg, Heather, Gargulak, Morgan, Kong, Amanda, Polhemus, Mark, Endy, Timothy, Thomas, Stephen J., Jarman, Richard G., Currier, Jeffrey R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684763/ https://www.ncbi.nlm.nih.gov/pubmed/31417556 http://dx.doi.org/10.3389/fimmu.2019.01778

Ejemplares similares

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)
por: Rivera, Luis, et al.
Publicado: (2021)

Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate
por: Patel, Sanjay S, et al.
Publicado: (2022)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination
por: López-Medina, Eduardo, et al.
Publicado: (2020)

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
por: Friberg, Heather, et al.
Publicado: (2022)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)
por: White, Laura J., et al.
Publicado: (2021)

97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View
por: Tricou, Vianney, et al.
Publicado: (2021)

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
por: LeFevre, Inge, et al.
Publicado: (2023)

Stochastic Model of the Adaptive Immune Response Predicts Disease Severity and Captures Enhanced Cross-Reactivity in Natural Dengue Infections
por: Nguyen, Hung D., et al.
Publicado: (2021)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
por: Moris, Philippe, et al.
Publicado: (2019)

Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and metabolic profiling
por: Waickman, Adam T., et al.
Publicado: (2019)

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study
por: Tricou, Vianney, et al.
Publicado: (2023)

Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity
por: Fang, Hengsheng, et al.
Publicado: (2021)

Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection
por: Friberg, Heather, et al.
Publicado: (2018)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
por: Patel, Sanjay S., et al.
Publicado: (2023)

Longitudinal Analysis of Dengue Virus–Specific Memory T Cell Responses and Their Association With Clinical Outcome in Subsequent DENV Infection
por: Sanchez-Vargas, Luis Alberto, et al.
Publicado: (2021)

Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques
por: McCracken, Michael K., et al.
Publicado: (2021)

Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection
por: Wegman, Adam D., et al.
Publicado: (2021)

Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003
por: Tu, Huy A., et al.
Publicado: (2020)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infections
por: Waickman, Adam T., et al.
Publicado: (2021)

Novel Potent Autophagy Inhibitor Ka-003 Inhibits Dengue Virus Replication
por: Limthongkul, Jitra, et al.
Publicado: (2023)

Social-ecological factors and preventive actions decrease the risk of dengue infection at the household-level: Results from a prospective dengue surveillance study in Machala, Ecuador
por: Kenneson, Aileen, et al.
Publicado: (2017)

Exploring the utility of social-ecological and entomological risk factors for dengue infection as surveillance indicators in the dengue hyper-endemic city of Machala, Ecuador
por: Lippi, Catherine A., et al.
Publicado: (2021)

Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1
por: Friberg, Heather, et al.
Publicado: (2020)

Analysis of cell-associated DENV RNA by oligo(dT) primed 5’ capture scRNAseq
por: Sanborn, Mark A., et al.
Publicado: (2020)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
por: Whitehead, Stephen S., et al.
Publicado: (2017)

mRNA-1273 vaccination protects against SARS-CoV-2–elicited lung inflammation in nonhuman primates
por: Waickman, Adam T., et al.
Publicado: (2022)

TAK1 inhibition attenuates both inflammation and fibrosis in experimental pneumoconiosis
por: Li, Jie, et al.
Publicado: (2017)

Pre-vaccination frequency of circulatory Tfh is associated with robust immune response to TV003 dengue vaccine
por: Izmirly, Abdullah M., et al.
Publicado: (2022)

TAZ inhibits osteoclastogenesis by attenuating TAK1/NF-κB signaling
por: Yang, Wanlei, et al.
Publicado: (2021)

Top Physics at ATLAS 003
por: Stavropoulos, G D
Publicado: (2004)

Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis
por: Carruthers, Jean, et al.
Publicado: (2016)

TAK1ng control: TAK1 restrains NLRP3 activation
por: Mangan, Matthew Stephen, et al.
Publicado: (2018)

923 Lactococcus garvieae infective endocarditis requiring valve replacement: First case in the United States
por: Sharngoe, Calden, et al.
Publicado: (2014)

Role of Humoral versus Cellular Responses Induced by a Protective Dengue Vaccine Candidate
por: Zellweger, Raphaël M., et al.
Publicado: (2013)

Maternally derived antibody titer dynamics and risk of hospitalized infant dengue disease
por: O’Driscoll, Megan, et al.
Publicado: (2023)

Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models
por: Shukla, Rahul, et al.
Publicado: (2020)

The origins of dengue and chikungunya viruses in Ecuador following increased migration from Venezuela and Colombia
por: Maljkovic Berry, Irina, et al.
Publicado: (2020)

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial
por: Martinez, Luis Javier, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qg54l433kgrbolg34qah86qo52